Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NMTC
stocks logo

NMTC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast NMTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMTC is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NMTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMTC is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.671
sliders
Low
3.00
Averages
3.00
High
3.00
Current: 0.671
sliders
Low
3.00
Averages
3.00
High
3.00
Maxim
Maxim
initiated
$3
2025-09-09
Reason
Maxim
Maxim
Price Target
$3
2025-09-09
initiated
Reason
Maxim initiated coverage of NeuroOne Medical with a Buy rating and $3 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for NeuroOne Medical Technologies Corp (NMTC.O) is -4.19, compared to its 5-year average forward P/E of -3.41. For a more detailed relative valuation and DCF analysis to assess NeuroOne Medical Technologies Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.41
Current PE
-4.19
Overvalued PE
-1.63
Undervalued PE
-5.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.88
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.04
Undervalued EV/EBITDA
-1.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
100.40
Current PS
0.00
Overvalued PS
325.57
Undervalued PS
-124.77
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NMTC News & Events

Events Timeline

(ET)
2025-08-18
08:33:30
NeuroOne Medical Secures FDA 510(k) Approval for OneRF Device
select
2025-08-14 (ET)
2025-08-14
07:39:35
NeuroOne Medical sees FY25 product revenue $8M-$10M vs. $3.5M last year
select
2025-08-14
07:39:22
NeuroOne Medical reports Q3 EPS (3c) vs. (10c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
10-07NASDAQ.COM
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates

  • Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.

  • Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.

  • Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.

  • NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.

[object Object]
Preview
2.0
10-01NASDAQ.COM
Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends

  • Biotech Stocks Performance: Biotech stocks experienced strong after-hours gains, with notable rebounds from small-cap companies like Ovid Therapeutics, NeuroOne Medical, and PepGen, driven by positive sentiment following Pfizer's drug price cuts and investment in domestic manufacturing.

  • Ovid Therapeutics Update: Ovid Therapeutics saw a 7.69% increase in after-hours trading, supported by a recent Buy rating from Lucid Capital and a narrower quarterly loss, alongside a $7 million royalty sale agreement related to future revenues.

  • PepGen's Recent Surge: PepGen's stock rose 3.03% after-hours, continuing a volatile week with over 120% growth, attributed to positive Phase 2 trial results for its myotonic dystrophy treatment and a successful $100 million public offering.

  • Reviva Pharmaceuticals and Anika Therapeutics: Reviva Pharmaceuticals gained 5.81% after-hours following a significant intraday surge, while Anika Therapeutics rose 5.53% ahead of its upcoming earnings report, despite a quiet news cycle for both companies.

[object Object]
Preview
9.0
08-18Newsfilter
NeuroOne® Obtains FDA 510(k) Approval for OneRF® Trigeminal Nerve Ablation System to Address Facial Pain

  • FDA Clearance: NeuroOne Medical Technologies has received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, aimed at treating trigeminal neuralgia through minimally invasive procedures.

  • Technology Features: The system utilizes a unique multi-contact RF probe to deliver targeted radiofrequency energy, enhancing safety and accuracy while potentially reducing procedural time and improving patient comfort.

  • Market Potential: This marks NeuroOne's entry into pain management therapies, with plans for a limited commercial launch in late 2025 and opportunities to expand into other neurological disorders and therapeutic applications.

  • Company Overview: NeuroOne focuses on developing minimally invasive solutions for various neurological conditions, aiming to improve patient outcomes and reduce procedural costs.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NeuroOne Medical Technologies Corp (NMTC) stock price today?

The current price of NMTC is 0.671 USD — it has decreased -1.47 % in the last trading day.

arrow icon

What is NeuroOne Medical Technologies Corp (NMTC)'s business?

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

arrow icon

What is the price predicton of NMTC Stock?

Wall Street analysts forecast NMTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMTC is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NeuroOne Medical Technologies Corp (NMTC)'s revenue for the last quarter?

NeuroOne Medical Technologies Corp revenue for the last quarter amounts to 1.70M USD, increased 105.39 % YoY.

arrow icon

What is NeuroOne Medical Technologies Corp (NMTC)'s earnings per share (EPS) for the last quarter?

NeuroOne Medical Technologies Corp. EPS for the last quarter amounts to -0.03 USD, decreased -70.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for NeuroOne Medical Technologies Corp (NMTC)'s fundamentals?

The market is revising Upward the revenue expectations for NeuroOne Medical Technologies Corporation (NMTC) for FY2025, with the revenue forecasts being adjusted by 4.32% over the past three months. During the same period, the stock price has changed by -15.36%.
arrow icon

How many employees does NeuroOne Medical Technologies Corp (NMTC). have?

NeuroOne Medical Technologies Corp (NMTC) has 17 emplpoyees as of December 05 2025.

arrow icon

What is NeuroOne Medical Technologies Corp (NMTC) market cap?

Today NMTC has the market capitalization of 33.55M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free